Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics


Alkermes plc - Ordinary Shares (ALKS): $26.09

0.89 (+3.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALKS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALKS POWR Grades

  • ALKS scores best on the Value dimension, with a Value rank ahead of 92.48% of US stocks.
  • ALKS's strongest trending metric is Momentum; it's been moving up over the last 179 days.
  • ALKS's current lowest rank is in the Momentum metric (where it is better than 24.37% of US stocks).

ALKS Stock Summary

  • ALKERMES PLC's stock had its IPO on July 16, 1991, making it an older stock than 85.1% of US equities in our set.
  • The price/operating cash flow metric for ALKERMES PLC is higher than 95.11% of stocks in our set with a positive cash flow.
  • Over the past twelve months, ALKS has reported earnings growth of 91.09%, putting it ahead of 84.15% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ALKERMES PLC are DZSI, PEAR, PTE, EMKR, and SQL.
  • Visit ALKS's SEC page to see the company's official filings. To visit the company's web site, go to www.alkermes.com.

ALKS Valuation Summary

  • ALKS's EV/EBIT ratio is -30.6; this is 455.81% lower than that of the median Healthcare stock.
  • ALKS's price/earnings ratio has moved down 27.1 over the prior 243 months.

Below are key valuation metrics over time for ALKS.

Stock Date P/S P/B P/E EV/EBIT
ALKS 2022-11-25 3.5 3.8 -30.8 -30.6
ALKS 2022-11-23 3.5 3.8 -30.9 -30.7
ALKS 2022-11-22 3.6 3.9 -31.2 -30.9
ALKS 2022-11-21 3.4 3.7 -30.2 -30.0
ALKS 2022-11-18 3.4 3.7 -29.8 -29.6
ALKS 2022-11-17 3.3 3.6 -28.7 -28.6

ALKS Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 55.61%.
  • The 4 year revenue growth rate now stands at 60.13%.
  • Its 2 year revenue growth rate is now at 0.57%.
ALKS's revenue has moved up $385,890,000 over the prior 70 months.

The table below shows ALKS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,131.584 51.018 -129.14
2022-06-30 1,173.368 133.17 -94.154
2022-03-31 1,200.866 168.539 -61.654
2021-12-31 1,173.751 101.715 -48.169
2021-09-30 1,129.283 138.037 -91.684
2021-06-30 1,100.154 115.463 -62.83

ALKS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALKS has a Quality Grade of B, ranking ahead of 88.71% of graded US stocks.
  • ALKS's asset turnover comes in at 0.582 -- ranking 63rd of 680 Pharmaceutical Products stocks.
  • OTLK, AVEO, and LXRX are the stocks whose asset turnover ratios are most correlated with ALKS.

The table below shows ALKS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.582 0.835 -0.047
2021-06-30 0.576 0.836 -0.029
2021-03-31 0.556 0.835 -0.050
2020-12-31 0.557 0.828 -0.061
2020-09-30 0.641 0.845 -0.034
2020-06-30 0.646 0.844 -0.076

ALKS Price Target

For more insight on analysts targets of ALKS, see our ALKS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.50 Average Broker Recommendation 1.88 (Hold)

ALKS Stock Price Chart Interactive Chart >

Price chart for ALKS

ALKS Price/Volume Stats

Current price $26.09 52-week high $32.79
Prev. close $25.20 52-week low $21.75
Day low $24.85 Volume 1,978,400
Day high $26.17 Avg. volume 1,541,865
50-day MA $23.15 Dividend yield N/A
200-day MA $26.13 Market Cap 4.29B

Alkermes plc - Ordinary Shares (ALKS) Company Bio


Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.


ALKS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream


Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about ALKERMES PLC that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Alkermes Supporting Local Communities

Alkermes respects the culture, customs and values of the people in the communities in which we operate.

Yahoo | November 28, 2022

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

Yahoo | November 23, 2022

How Alkermes (ALKS) Stock Stands Out in a Strong Industry

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | November 23, 2022

Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 29, 2022 at 2:40 p.m. ET ( 7:40 p.m. GMT ). The live webcast may be accessed under the

Alkermes | November 22, 2022

Alkermes plc: Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

DUBLIN, Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesda…

Finanz Nachrichten | November 22, 2022

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo 8.44%
3-mo 6.45%
6-mo -10.99%
1-year 18.00%
3-year 28.78%
5-year -51.42%
YTD 12.17%
2021 16.59%
2020 -2.21%
2019 -30.87%
2018 -46.08%
2017 -1.53%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8551 seconds.